Sign in

    John Gregory Dean

    Managing Director and Senior Equity Research Analyst at Oppenheimer & Co. Inc.

    John Gregory Dean is a Managing Director and Senior Equity Research Analyst at Oppenheimer & Co. Inc., specializing in the technology and internet sectors with a focus on covering leading public companies in these industries. He is recognized for his analytical rigor and consistent track record, providing insightful investment research and maintaining highly ranked performance metrics among Wall Street analysts, with a documented success rate above industry averages and strong returns as measured by independent platforms. Dean began his career in equity research in the early 2000s, previously holding analyst roles at firms such as Credit Suisse and SunTrust Robinson Humphrey prior to joining Oppenheimer. He holds FINRA Series 7, 63, 86, and 87 licenses and is a CFA charterholder, underscoring his professional credentials and commitment to industry standards.

    John Gregory Dean's questions to Harmony Biosciences Holdings (HRMY) leadership

    John Gregory Dean's questions to Harmony Biosciences Holdings (HRMY) leadership • Q4 2024

    Question

    John Gregory Dean, on behalf of Frank Brisebois, asked for the rationale behind the high confidence in Pitolisant HD's likelihood of success in idiopathic hypersomnia (IH) patients.

    Answer

    Dr. Kumar Budur, Chief Medical and Scientific Officer, explained the confidence stems from two factors. First, the original INTUNE study showed clear efficacy in the open-label phase. Second, a body of evidence from all pitolisant trials demonstrates a clear dose-response and exposure-response relationship. He also noted the new trial will use a more straightforward parallel-arm design, aiding data interpretation.

    Ask Fintool Equity Research AI